Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

NCT03303105 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Migraine

Interventions

DRUG: TEV-48125
DRUG: TEV-48125

Sponsor

Otsuka Pharmaceutical Co., Ltd.